FOR RESEARCH USE ONLY
Predominantly preclinicalRecovery research

KPV

Alpha-MSH C-terminal tripeptide researched for anti-inflammatory and gut-mucosal repair applications.

01NF-κB02Mucosal inflammation03Innate immunity
Molecular signature / kpv
Structural identity

Three-amino-acid C-terminal fragment of α-MSH

Also known as

Lys-Pro-Val · α-MSH C-terminal tripeptide

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). It retains the potent anti-inflammatory activity of the parent hormone without its pigmentation or appetite effects, and is studied across inflammatory bowel disease, dermatological inflammation, mast-cell modulation and wound healing.

The research question

KPV retains anti-inflammatory activity associated with part of α-MSH without sharing every effect of the parent hormone. NF-κB signalling and epithelial inflammation are central themes, particularly in intestinal and skin models.

Section 02

Mechanism & research themes

Enters cells and translocates to the nucleus to inhibit NF-κB activation, suppressing downstream pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). Also stabilises mast cells and modulates innate immune responses.

01

Broad anti-inflammatory activity via NF-κB suppression

02

Improved outcomes in IBD and colitis animal models

03

Reduced inflammatory dermatological lesions in research

04

Mast-cell stabilisation relevant to allergic and MCAS research

05

Antimicrobial activity against several common pathogens

06

Favourable tolerability with minimal reported side effects

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Predominantly preclinical

Most direct evidence comes from cell and animal inflammation models. Oral, topical and injectable routes pose different bioavailability questions and should be assessed separately.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 200–500mcg subcutaneously once daily, or higher oral/encapsulated doses (approximately 500mcg–1mg) for gut-targeted protocols. Cycles typically run 4–8 weeks.

Reported persistence

Plasma half-life is short (approximately 30–60 minutes); local tissue effects persist longer.

Calculator starting point

0.5 mg per reference dose

7 doses per week · 4-week cycle

2 mL default reconstitution volume

200–500 mcg/day SC, short cycles.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate KPV
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 10mg vial with 2–4mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently.

Storage reference

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Human RCT data remains limited; most evidence is preclinical or early-phase.

L2

Oral bioavailability is modest — encapsulation or compounding is typically required for gut-targeted use.

L3

Long-term safety dataset is not yet well characterised.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only